193 related articles for article (PubMed ID: 28389324)
1. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
[TBL] [Abstract][Full Text] [Related]
2. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
[TBL] [Abstract][Full Text] [Related]
3. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
4. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
[TBL] [Abstract][Full Text] [Related]
5. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
6. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
7. Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone.
Turner RT; Lotinun S; Hefferan TE; Morey-Holton E
J Appl Physiol (1985); 2006 Sep; 101(3):881-6. PubMed ID: 16675609
[TBL] [Abstract][Full Text] [Related]
8. Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.
Le Henaff C; Ricarte F; Finnie B; He Z; Johnson J; Warshaw J; Kolupaeva V; Partridge NC
J Bone Miner Res; 2020 Apr; 35(4):714-724. PubMed ID: 31793033
[TBL] [Abstract][Full Text] [Related]
9. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
10. Abaloparatide: First Global Approval.
Shirley M
Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
[TBL] [Abstract][Full Text] [Related]
11. Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.
Sato T; Verma S; Khatri A; Dean T; Goransson O; Gardella TJ; Wein MN
JBMR Plus; 2021 May; 5(5):e10441. PubMed ID: 33977197
[TBL] [Abstract][Full Text] [Related]
12. Type-1 parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptors activate phospholipase C in response to carboxyl-truncated analogs of PTH(1-34).
Takasu H; Bringhurst FR
Endocrinology; 1998 Oct; 139(10):4293-9. PubMed ID: 9751512
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of parathyroid hormone, parathyroid hormone-related protein, and abaloparatide on collagen 1 expression by mouse cementoblasts and mouse tooth root density.
Hsu C; He Z; Le Henaff C; Partridge NC
Am J Orthod Dentofacial Orthop; 2023 Mar; 163(3):378-388.e1. PubMed ID: 36543659
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
15. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
[TBL] [Abstract][Full Text] [Related]
16. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
[TBL] [Abstract][Full Text] [Related]
17. Abaloparatide for the treatment of postmenopausal osteoporosis.
Pietrogrande L; Raimondo E
Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
[TBL] [Abstract][Full Text] [Related]
18. Human parathyroid hormone (PTH)-related protein and human PTH: comparative biological activities on human bone cells and bone resorption.
Fukayama S; Bosma TJ; Goad DL; Voelkel EF; Tashjian AH
Endocrinology; 1988 Dec; 123(6):2841-8. PubMed ID: 2848688
[TBL] [Abstract][Full Text] [Related]
19. Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide.
Ardura JA; Portal-Núñez S; Alonso V; Bravo B; Gortazar AR
Trends Endocrinol Metab; 2019 Oct; 30(10):756-766. PubMed ID: 31409530
[TBL] [Abstract][Full Text] [Related]
20. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
